week of the implantation. He was treated with a tapering dose of prednisone. Because he had a hypercoagulable condition, he was treated with warfarin and therefore had not been placed on clopidogrel before or after the procedure. After seven months and two courses of prednisone, the chest pain and palpitations have resolved and the headaches have improved.
The most important observation of this study was that 67% of the patients who had new onset or increased frequency and severity of MHA tested positive for nickel hypersensitivity. The two patients who also experienced symptoms but were not allergic to nickel had large ASD devices (38 mm). The sample size is small; nevertheless, these observations raise intriguing hypotheses.
One possible mechanism to explain the new onset or exacerbation of MHA is that a local inflammatory reaction to the implanted device results in the formation of platelet adhesions. These substances could then embolize to the brain, causing microinfarcts and MHA. An observation that lends support to this hypothesis is that five of the patients noted a marked increase in frequency of MHA shortly after discontinuing clopidogrel, suggesting that the pharmacologic suppression of platelet aggregation on the implanted device may be preventing embolization. One other report has documented the benefit of clopidogrel in reducing MHA after nitinol device implantation (8) . All five patients noted an improvement in MHA after re-starting clopidogrel. However, there was no evidence of abnormal MRI lesions in the two cases with the most severe MHA. In addition, follow-up transesophageal echocardiography did not show any thrombus on any of these Amplatzer devices. Therefore, there is no evidence for thrombus formation as the etiology of these neurologic symptoms.
An alternative mechanism to explain new onset or exacerbation of MHA is that a localized reaction around the device releases inflammatory mediators into the left atrium, which then travel to the cerebral circulation and induce MHA. Presumably the inflammation is greater if the patient is sensitive to nickel, but an exaggerated response may occur without nickel allergy and produce the same symptom complex, especially if a large device is implanted. This may explain why MHA are more likely to occur with ASD closure devices. This hypothesis opens research avenues to assess the effect of chemokines or other inflammatory proteins as primary triggers for MHAs in patients with or without implanted devices. This concept is consistent with the observation that closure of PFO or ASD leads to a dramatic reduction or abolition of MHAs in 75% of patients (1) . The observation that these patients responded dramatically and rapidly to administration of clopidogrel suggests that this drug may be acting as an antiinflammatory agent, either to decrease the release of the trigger chemicals from the inflammatory site in the left atrium or by acting on nociceptive neural adenosine receptors to inhibit the migrainous response to inflammatory byproducts. The initial recognition of nickel hypersensitivity as a potential problem occurred with our sentinel case. Subsequently, an attempt was made to contact previous patients that we had treated. All prospective patients thereafter were screened for nickel allergy. This selection bias captured all of the patients who complained of an adverse event, but the study population does not represent all of the patients without symptoms who might have a positive nickel allergy skin test result. This report of a 27% (10 of the 37) positive nickel allergy rate is therefore likely exaggerated.
In conclusion, new onset or increased frequency and severity of MHA after interatrial communication closure is associated with nickel hypersensitivity and large ASD devices. This phenomenon may be related to byproducts of an exaggerated inflammatory response. These events may persist for three to six months, but all eventually resolved. The MHAs and aura respond dramatically to clopidogrel. A larger prospective trial evaluating the safety of ASD and PFO closure in patients with nickel allergy is warranted. 
